What type of drug is Verzenio?
Medically reviewed by N. France, BPharm. Last updated on Feb 4, 2021.
Verzenio (abemaciclib) is a small molecule drug and kinase inhibitor used to treat patients with advanced or metastatic (cancer that has spread) breast cancer. Verzenio is an ATP-competitive inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4 and CDK6).
Verzenio is used:
- In postmenopausal women taking an aromatase inhibitor as initial endocrine-based therapy for hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced for metastatic breast cancer.
- In women taking fulvestrant (Faslodex) for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy.
- As a monotherapy in adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy and chemotherapy for metastatic disease.
- Food and Drug Administration (FDA). Verzenio. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208716s004lbl.pdf. [Accessed February 4, 2021].
- Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825-837. doi:10.1007/s10637-014-0120-7.
Related Medical Questions
- Is Verzenio better than Ibrance?
- Can you take Verzenio after Ibrance fails?
- How long do you take Verzenio for?
- How long does it take Verzenio to work?
- Is Verzenio (abemaciclib) a chemo drug?
- How effective is Verzenio?
- Verzenio Information for Consumers
- Verzenio Information for Healthcare Professionals (includes dosage details)
- Side Effects of Verzenio (detailed)